Resurgence of a Forgotten Opioid as a Deadly Street Drug

Nitazenes, highly potent synthetic opioids, have resurfaced as a major and often unseen threat in the overdose crisis due to their extreme potency and detection challenges. Experts emphasize the need for increased awareness, testing, and harm reduction strategies to combat this emerging public health emergency.
Recent research highlights the alarming rise of nitazenes, a class of highly potent synthetic opioids, which are reemerging as dangerous agents in the ongoing overdose crisis. Originally developed in the 1950s, nitazenes were never approved for clinical use and are now illicitly circulating on the street and online. These substances are over 20 times more potent than fentanyl and hundreds to thousands of times more potent than morphine, making them exceedingly dangerous.
Nitazenes can be found in various forms, including liquids, pills, or powders, often sold through social media platforms and on illicit markets since 2019. Because they were never meant for human consumption and are not approved for medical use, they are classified as Schedule I drugs and pose significant detection challenges since standard drug tests often miss their presence.
The growing presence of nitazenes represents a severe threat, especially to individuals with opioid use disorder. They are frequently mixed into counterfeit pills or street drugs such as fentanyl and methamphetamine, often unknowingly ingested by users. This clandestine mixing increases overdose risks, as patients may require higher or repeated doses of naloxone, a common overdose reversal medication.
A report from the Tennessee State Unintentional Drug Overdose Reporting System identified 92 fatalities involving nitazenes between 2019 and 2023. Notably, in Tennessee, naloxone—a life-saving drug—was administered in only one-third of these deaths, underscoring the difficulty in recognizing and responding to overdoses involving these potent substances.
Experts emphasize that many users are unaware of consuming nitazenes, as these are often adulterants in pills marketed as other opioids. Addressing this emerging threat necessitates a collaborative approach involving clinicians, public health agencies, law enforcement, and community organizations to promote harm reduction, expand testing capabilities, and increase awareness.
Recommendations include broadening access to advanced drug testing strips capable of detecting nitazenes and providing at-risk populations with take-home naloxone, education, and addiction treatment options. Public health officials warn that without swift, coordinated action, the spread of these ultra-potent opioids could exacerbate overdose morbidity and mortality.
Moving forward, research calls for generating human clinical data to better understand the long-term impacts, metabolism, and treatment responses related to nitazenes. As the opioid crisis evolves, continuous vigilance and innovative strategies are essential to prevent further tragedies involving these hidden but deadly substances.
Source: https://medicalxpress.com/news/2025-09-forgotten-opioid-resurfaced-lethal-street.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Brain Peptide ODN Enhances Glucose Regulation and Suppresses Hunger in Animal Studies
New research reveals that the brain-derived peptide ODN can suppress appetite and improve glucose regulation without side effects, opening new avenues for obesity and diabetes treatment.
T Cells in the Healthy Brain: Unveiling a Gut-Fat-Brain Connection
New studies reveal that T cells naturally reside in the healthy brain, originating from the gut and fat tissue, highlighting a novel gut-fat-brain axis that influences brain function and health.
Aficamten Demonstrates Superior Efficacy to Metoprolol in Treating Symptomatic Obstructive Hypertrophic Cardiomyopathy
Aficamten has shown to be more effective than metoprolol in improving symptoms and exercise capacity in patients with obstructive hypertrophic cardiomyopathy, according to a recent Phase III trial. Find out more about this groundbreaking research.
New Genetic Discovery Offers Hope for Chronic Pain Treatment
Researchers have identified a new genetic factor involved in chronic pain, revealing a promising target for innovative pain therapies that could reduce reliance on opioids. The discovery centers around the SLC45A4 gene, which encodes a neuronal polyamine transporter, offering new hope for safe and effective pain management.